NCT07171983RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
A 2-Part, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986454 in Participants With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid Arthritis
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 11 Sept 2025
- Start date
- 27 Feb 2026
- Primary completion date
- 28 Jun 2027
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07171983
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 46
- From 27 Feb 2026 to the primary completion date, 28 Jun 2027
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants must not have any significant medical condition, with the exception of Rheumatoid Arthritis (including but not limited to, neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders) that, in the Investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study.
- Participants must not have any condition aside from RA that confounds the ability to interpret data from the study.
- Participants must not have severe Rheumatoid Arthritis as assessed by Disease Activity Score 28 c-reactive protein (DAS28-CRP) at screening or Day -1.
Other
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Participants with Rheumatoid Arthritis must have onset after age 18.
- Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA.
- Participants must have evidence of swelling in at least 1 joint of the hand or wrist by clinical examination at screening and Day -1.
- Participants must have been an incomplete responder to prior methotrexate (MTX) treatment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Apollo Hospitals Ahmedabad Coordinator of this site? Confirm its status | Ahmedabad | India | Recruiting |
| Local Institution - 0003 Coordinator of this site? Confirm its status | Bangalore | India | Not yet recruiting |
| Local Institution - 0007 Coordinator of this site? Confirm its status | Bhubaneswar | India | Active, not recruiting |
| Local Institution - 0002 Coordinator of this site? Confirm its status | Hyderabad | India | Not yet recruiting |
| Nizams Institute of Medical Sciences Coordinator of this site? Confirm its status | Hyderabad | India | Recruiting |
| Local Institution - 0009 Coordinator of this site? Confirm its status | Mysuru | India | Not yet recruiting |
| All India Institute of Medical Sciences (AIIMS) - Nagpur Coordinator of this site? Confirm its status | Nagpur | India | Recruiting |
| Life Point Mutispecialty Hospital Pvt. Ltd. Coordinator of this site? Confirm its status | Pune | India | Recruiting |
| Krishna Institute of Medical Sciences Limited Coordinator of this site? Confirm its status | Secunderabad | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.